Spots Global Cancer Trial Database for Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas
Official Title: A Study of Surufatinib Neoadjuvant Therapy for Locally Advanced Primary Saliary Gland Adenocarcinoma：a Single-arm, Prospective,Open Label Study
Study ID: NCT05013515
Conditions
Interventions
Study Description
Brief Summary: The objective is to investigate the efficacy and safety of Surufatinib Neoadjuvant Therapy for Locally Advanced Primary Saliary Gland Adenocarcinoma.
Detailed Description: The purpose of this study was to explore whether the efficacy and survival time of patients with local advanced primary salivary gland adenocarcinoma could be further improved through the treatment of Surufatinib neoadjuvant for local advanced primary salivary gland adenocarcinoma, and to explore the safety and tolerability of this regimen.A Study of Surufatinib Neoadjuvant Therapy for Locally Advanced Primary Saliary Gland Adenocarcinoma：a Single-arm, Prospective,Open Label Study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, , China
Contact Details
Name: Min Ruan, MD
Affiliation: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
